OKUR
OnKure Therapeutics, Inc. NASDAQ Listed Apr 8, 2021$3.89
Mkt Cap $157.5M
52w Low $2.23
52.7% of range
52w High $5.38
50d MA $4.19
200d MA $3.64
P/E (TTM)
-1.1x
EV/EBITDA
—
P/B
0.9x
Debt/Equity
0.0x
ROE
-105.9%
P/FCF
-1.0x
RSI (14)
39.80
ATR (14)
$0.31
Beta
0.15
50d MA
$4.19
200d MA
$3.64
Avg Volume
133.8K
OnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer. The company focuses on developing selective inhibitors of histone deacetylases. Its portfolio includes OKI-179, an inhibitor for the treatment of both hematological and solid tumors. The company was incorporated in 2011 and is based in Boulder, Colorado.
6707 Winchester Circle · Boulder, CO 80301 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 4, 2026 | AMC | -0.54 | -0.31 | +42.1% | 4.10 | +0.7% | +1.5% | -0.2% | -0.2% | -1.9% | +0.7% | — |
| May 5, 2026 | AMC | -0.81 | -1.11 | -37.0% | 4.52 | -4.0% | -10.0% | -2.7% | -1.3% | -12.0% | -1.5% | — |
| Mar 12, 2026 | AMC | -1.15 | -0.99 | +13.9% | 3.52 | +6.2% | +7.4% | +3.2% | +3.1% | -0.2% | +9.2% | — |
| Nov 6, 2025 | AMC | -1.20 | -1.09 | +9.2% | 3.16 | -2.5% | -7.0% | +4.4% | +3.3% | -2.8% | +1.9% | — |
| Aug 12, 2025 | AMC | -1.23 | -1.14 | +7.3% | 2.00 | +9.5% | +20.0% | +11.2% | -5.2% | +10.7% | -2.1% | — |
| May 6, 2025 | AMC | -1.32 | -1.19 | +9.8% | 2.23 | +0.9% | -3.6% | -7.0% | -4.0% | +1.6% | -5.6% | — |
| Mar 10, 2025 | AMC | -0.86 | -1.37 | -59.3% | 4.96 | +5.8% | -0.2% | -3.2% | -3.5% | -0.2% | +4.6% | — |
| Nov 7, 2024 | AMC | -0.97 | -1.10 | -13.4% | 17.19 | -1.1% | +2.3% | -0.2% | -1.5% | -2.4% | +0.1% | — |
| Aug 13, 2024 | AMC | -1.00 | -1.60 | -60.0% | 13.80 | -4.3% | +6.5% | +6.1% | -0.6% | +1.9% | +0.0% | — |
| May 7, 2024 | AMC | -0.37 | -0.25 | +32.4% | 17.40 | +0.6% | +5.2% | +1.6% | -2.7% | -12.2% | +1.9% | — |
| Mar 28, 2024 | AMC | -5.78 | -7.00 | -21.1% | 16.60 | -0.6% | +2.4% | +0.6% | +0.0% | +1.2% | -1.2% | — |
| Dec 31, 2023 | AMC | -5.78 | -7.00 | -21.1% | — | — | — | — | — | — | — | — |
| Nov 13, 2023 | AMC | -5.71 | -5.70 | +0.3% | 62.50 | -0.6% | +1.4% | +4.3% | -7.7% | +10.8% | -7.4% | — |
| Sep 30, 2023 | AMC | -5.71 | -1.44 | +74.8% | — | — | — | — | — | — | — | — |
| Jun 30, 2023 | AMC | -5.30 | -0.61 | +88.4% | 65.60 | +12.0% | -2.3% | +5.9% | +0.0% | -0.6% | +8.4% | — |
| Mar 31, 2023 | AMC | -6.04 | -0.65 | +89.2% | 59.80 | +0.3% | -6.0% | -3.2% | +3.9% | -0.9% | +7.2% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.78 | $3.86 | +2.1% | +3.2% | +3.1% | -0.2% | +9.2% | -4.3% |
| Aug 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.82 | $2.76 | -2.1% | -2.5% | +1.8% | +0.4% | -2.1% | +0.7% |
| Mar 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.82 | $4.91 | +1.9% | +1.9% | +1.8% | +0.0% | +1.0% | -1.8% |
| Mar 11 | Oppenheimer | Maintains | Outperform → Outperform | — | $4.96 | $5.25 | +5.8% | -0.2% | -3.2% | -3.5% | -0.2% | +4.6% |
| Nov 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.19 | $17.00 | -1.1% | +2.3% | -0.2% | -1.5% | -2.4% | +0.1% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 22, 2026 | Saccomano Nicholas A | President and CEO | Sell | 86 | $4.40 | $378 | 11,247 | -2.77% | -2.19% |
| Jun 22, 2026 | Leverone Jason A. | Chief Financial Officer | Sell | 303 | $4.40 | $1K | 18,802 | -2.77% | -2.19% |
8-K · 5.02
!!! Very High
OnKure Therapeutics, Inc. -- 8-K 5.02: Executive Change
Aug 13
8-K · 1.01
! Medium
Unknown — 8-K 1.01: Equity Issuance
OKUR's equity issuance dilutes existing shareholders' ownership percentages and voting power, likely pressuring the stock price unless the capital raised funds high-return investments or addresses urgent operational needs.
Mar 30
8-K
Unknown — 8-K Filing
Okur Therapeutics' on-track PI3K-alpha pipeline, particularly the PIKture-01 trial for OKI-219, suggests potential future catalyst events that could drive clinical validation and reduce clinical-stage development risk for investors.
Mar 12
Institutional (13F) — Top 0
All ↗
No 13F holders found.
Mutual Funds / ETFs (N-PORT) — Top 3
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Ultra-Small Company Fund | 16,293 | $67K | Mar 2026 |
| 2 | Avantis Total Equity Markets ETF | 504 | $1K | Feb 2026 |
| 3 | Russell 2000(R) 1.5x Strategy Fund | 7 | $32 | Jun 2026 |
Valuation
Market Cap
$157.5M
Enterprise Value
-$6.5M
P/E (TTM)
-1.11x
Forward P/E
—
PEG Ratio
-0.06x
P/B
0.94x
P/S
—
P/FCF
-1.01x
EV/EBITDA
—
Shares Out
13.5M
Financials (TTM)
Revenue
$0
Net Income
-$58.7M
EBITDA
-$58.1M
Free Cash Flow
-$51.9M
Op Cash Flow
-$51.8M
EPS Basic
$-4.40
EPS Diluted
$-3.50
EPS Forward
$-2.65
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$62.1M
Total Liab.
$5.9M
Total Equity
$56.2M
Cash
$59.0M
LT Debt
$0
Book Value/Sh
$4.16
Debt/Equity
0.01x
Current Ratio
10.28
Quick Ratio
10.28
Returns & Growth
ROE
-105.9%
ROA
-95.8%
ROIC
-110.9%
Rev Growth YoY
+0.0%
EPS Growth YoY
-11.4%
Price Returns
2W
-4.2%
1M
-5.6%
3M
-5.6%
6M
+43.5%
12M
+37.9%
Technicals
52W High
$5.38
52W Low
$2.23
50d MA
$4.19
200d MA
$3.64
RSI (14)
39.80
ATR (14)
$0.31
Beta
0.15
Avg Volume
134K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$35.00
High
$35.00
Low
$35.00
Median
$35.00
Data updated apr 26, 2026 5:13pm
· Source: financialmodelingprep.com